BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Methods Development

WuXi Biologics Partners With Vertex To Advance Trispecific T Cell Engager For Autoimmune Diseases

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has signed a license ...

February 04, 2026 | News

Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...

February 03, 2026 | News

AstraZeneca Commits $15 Billion Investment To Expand R&D And Manufacturing Footprint In China Through 2030

Landmark investment will expand AstraZeneca’s capabilities to discover, develop, and manufacture transformative new treatments in China In...

February 03, 2026 | News

Merck Strengthens India As A Strategic Healthcare R&D Growth Engine With New Innovation Hub

A workplace designed for long-term growth, efficiency, and innovation Elevating Merck Healthcare’s R&D India Hub as a premier talent powerho...

February 02, 2026 | News

Fidēs Launches Science Led Imaging CRO Focused On Early Phase Clinical Decision Making

Fidēs announced its launch as a new imaging contract research organization (iCRO) designed specifically for early-phase clinical development, where imagin...

February 02, 2026 | News

Samsung Biologics Earns EcoVadis Platinum Sustainability Rating

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the EcoVadis...

January 30, 2026 | News

HKeyBio Introduces Translational Preclinical Strategy To Rethink Asthma And Allergy Drug Development

HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, announced a translational preclinical strategy, HKEY-AIRxTM1.0...

January 29, 2026 | News

WuXi Biologics And HanchorBio Inc. Sign Strategic Collaboration To Advance Next Generation Fusion Biologics

WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a globa...

January 27, 2026 | News

Blau Farmacêutica Achieves End To End Development Of Pembrolizumab Biosimilar In Brazil

Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market (B3) and a regional leader in hospital pharmaceuticals w...

January 27, 2026 | News

Samsung Biologics Strengthens Long Term Growth Platform With Solid 2025 Financial Performance

Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion Maintained momentum through consistent ...

January 22, 2026 | Company results

Dr Chris Chen Positions WuXi Biologics As The Defining Force Shaping The Future Of Global CRDMO Innovation

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects ...

January 19, 2026 | News

Oricell Raises 70M$ In Series C1 To Advance First In Class CAR T Therapy For Liver Cancer

Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced the closing of a $70M Ser...

January 14, 2026 | News

WuXi Biologics Secures UK MHRA GMP Clearance For Wuxi Ophthalmic Manufacturing Sites

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing ...

January 14, 2026 | News

Esco Aster Provides CMC Manufacturing Support For Shine On Biomedical HLA G Targeted Exosome Programme

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Bio...

January 07, 2026 | News

Stay Connected